2009 Diabetes Vaccines 
pharmaphorum
MARCH 11, 2022
After a period where vaccine development had fallen away, suddenly it is back in the limelight. However, for those individuals working on vaccine development, the pandemic has proven to be a validation of the important work being carried out in the field. billion from its vaccine in 2021. The ‘poor relation’.
Express Pharma
JUNE 12, 2024
Covid-19 promoted India to the centre stage of global vaccine export as the consumerisation of health providing an impetus for vaccines and prompt approvals. ILR(2009)Supp. (2)Delhi Union of India (4) (2013 (6) SCC 1), the Division Bench of Delhi High Court in the case of F. Hoffmann-LA Roche and Ors. Vs. Cipla (5).
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
JUNE 21, 2024
Covid-19 promoted India to the centre stage of global vaccines export as consumerisation of health providing an impetus for vaccines and prompt approvals. ILR(2009)Supp.(2)Delhi Union of India4 (2013 (6) SCC 1), the Division Bench of Delhi High Court in the case of F. Hoffmann-LA Roche and Ors. Vs. Cipla5.
PharmaShots
APRIL 13, 2023
2009 was a challenging year for multinational companies due to the recession and currency fluctuations Johnson & Johnson's performance graph declined by 2.9% Despite a challenging year, Johnson & Johnson acquired Cougar and Elan Pfizer's 2009 performance was significant as compared to 2008 with the addition of Wyeth.
pharmaphorum
DECEMBER 2, 2020
Others rapidly followed, including Glucotrol, aimed at diabetics, and Procardia, an anti-hypertensive. Since the turn of the millennium, Pfizer has embarked on a series of mega-mergers, gobbling up Warner-Lambert in 2000, Pharmacia and Upjohn in 2002, Wyeth in 2009, and Medivation in 2016. The era of mega-mergers.
pharmaphorum
FEBRUARY 26, 2021
During this tenure, J&J entered into the areas of vision care, mechanical wound closure and diabetes management. The litigation was settled in 2009, when Boston Scientific agreed to pay $716 million in September and an additional $1.73 Acquisitions post-Janssen. Between 1976 and 1989, James E. Burke was chairman and CEO of J&J.
pharmaphorum
JANUARY 5, 2021
Anyone who proposed that a novel, deadly virus would spread, with a vaccine developed demonstrating 95% efficacy, and approved for patients in less than a year would have been scoffed at. These changes are likely to reduce only slowly in the Vaccine+ environment, and will not be entirely reversed.
Expert insights. Personalized for you.
81 
Let's personalize your content